<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02102477</url>
  </required_header>
  <id_info>
    <org_study_id>SPCG-15</org_study_id>
    <nct_id>NCT02102477</nct_id>
  </id_info>
  <brief_title>Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer</brief_title>
  <acronym>SPCG-15</acronym>
  <official_title>Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olof Akre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, open randomized phase III surgical trial seeks to study whether radical
      prostatectomy (with or without the combination of external radiation) improves
      prostate-cancer specific survival in comparison with primary radiation treatment and hormonal
      treatment among patients diagnosed with locally advanced (T3) prostate cancer. Untreated or
      conservatively treated locally advanced prostate cancer is associated with high mortality.
      Modern curative treatment for advanced solid malign tumors include surgery and/or radiation
      plus attempted chemotherapy if available to achieve both local control and elimination of
      potential micro metastases. Whereas there is evidence that surgery can cure localized
      prostate cancer, there are no clinical trials of multi-modal treatment of locally advanced
      prostate cancer that includes surgical removal of the prostate.

      One potential advantage of adding prostatectomy to the treatment of LAPC is that removing the
      prostate enables a full pathological assessment of the tumor characteristics and thus a
      better estimation of the risk of recurrence. Surgical treatment could thus reduce the numbers
      needed to treat with chemotherapy and radiation, and thus improve quality of life after
      treatment. In addition, evidence indicate that residual cancer in the prostate occurs in 25%
      after radiation treatment (56)and surgical removal of the prostate may improve survival
      beyond what can be achieved by radiation and ADT. On the other hand, patients treated with
      surgery, radiation and hormones will experience side effects of all three treatment
      modalities and might fare better if radiotherapy plus hormones can provide oncological
      control without prior surgery.

      A randomized clinical trial comparing two multimodal treatment regimens of which one includes
      a radical prostatectomy is therefore warranted.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cause specific survival</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Cause-specific survival (CSS), time to event. Cause-specific mortality data will be ascertained through the nationwide Cause-of-Death Register.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>metastasis free survival</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Composite endpoint of time to metastasis and survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At 1,2,5 and 10 years after randomization</time_frame>
    <description>Questionnaire-based evaluation of general psychological health, urinary health, bowel health, and sexual health.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health-care consumption</measure>
    <time_frame>Annually up to 10 years</time_frame>
    <description>Annual Defined Daily Dose (DDD) of analesics annual number of days of hospitalization</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Prostatectomy/Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with locally advanced prostate adenocarcinoma recieves Prostatectomy/Surgery with or without adjuvant or salvage radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy with adjuvant androgen deprivation therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with locally advanced prostate adenocarcinoma treated with adjuvant androgen deprivation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prostatectomy/Surgery</intervention_name>
    <description>Radical prostatectomy with or without adjuvant or salvage radiotherapy</description>
    <arm_group_label>Prostatectomy/Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiotherapy with adjuvant androgen deprivation therapy</intervention_name>
    <description>Radiotherapy with adjuvant androgen deprivation therapy</description>
    <arm_group_label>Radiotherapy with adjuvant androgen deprivation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≤75, at the time of randomization

          -  Newly diagnosed prostatic adenocarcinoma morphologically confirmed and untreated

          -  The transrectal ultrasound (TRUS-guided) biopsy with at least 10 cores (regarding
             handling of biopsies)

          -  The general condition and mental status of patients shall permit observation in
             accordance with the study protocol

          -  Tumor stage (T, M, N):

        T3 stage Significant extra-capsular tumor extension M0 (no sign of distant metastases) N0
        (no sign of macroscopic lymph-node metastases)

          -  Presence Gleason grade pattern 4

          -  Eligible for either treatment

          -  Signed Informed consent

        Exclusion Criteria:

          -  Patients with a PSA value of &gt; 100 ng/mL

          -  Patients with a history of other cancer diagnoses (apart from non-melanoma skin
             cancer)

          -  Clinical significant abnormal laboratory values at the discretion of the investigator,
             e.g. severe kidney function GFR &lt; 30 ml/ml or elevated liver transaminases above &gt; 10
             ULN

          -  Any medical condition which, in the opinion of the investigator, might interfere with
             the evaluation of the study objectives
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Stranne, M.D ass prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Department of Urology, SE- 413 45 Gothenburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Camilla Thellenberg Karlsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University Hospital, Department of Radiation Science, SE-901 87 Umeå Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva M Johansson, R.N PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institute, Nobelsväg, SE- 171 77 Solna, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gunnar Steineck, M.D Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institute, Nobelsväg, SE-171 77 Solna, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus Brasso, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, department Urology, DK-2001-Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter M Meidahl Petersen, M.D ass prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Region h, Department of Oncology, Blegdamsvej 9, DK- 2001, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bjørn Brennhovd, M.D ass.prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, Department of Urology, P.O Box 4950 Nydalen, N-0424, Oslo Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Lilleby, M.D ass.prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, Department of Radiation Therapy, P.O Box 4950, N-0424, Nydalen Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antti Rannikko, M.D ass.prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Department Urology,Stenbäckinkatu 9, FIN-00290 Helsinki , Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauri Kouri, M.D PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Department Urology,Stenbäckinkatu 9, FIN-00290 Helsinki , Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tuomas Mirtti, M.D PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Department Urology,Stenbäckinkatu 9, FIN-00290 Helsinki , Finland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olof Akre, Ass.prof.</last_name>
    <phone>+46-(0)8- 517 700000</phone>
    <email>olof.akre@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet, Region h, Department Oncology</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2001</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter M Meidahl Petersen, M.D ass</last_name>
    </contact>
    <investigator>
      <last_name>Peter M Meidahl Petersen, M.D ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshopsitalet Department urology</name>
      <address>
        <city>Copenhagen</city>
        <zip>SE- 2001</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Klaus Brasso, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Klaus Brasso, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital, Department of Urology</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antti Rannikko, M.D ass prof</last_name>
    </contact>
    <investigator>
      <last_name>Antti Rannikko, M.D ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauri Kouri, M.D PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tuomas Mirtti, M.D PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hopsital, Department Urology</name>
      <address>
        <city>Nydalen-Oslo</city>
        <zip>N-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjorn Brennhovd, M.D ass prof</last_name>
    </contact>
    <investigator>
      <last_name>Bjorn Brennvold, M.D ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Department of radiation Therapy</name>
      <address>
        <city>Nydalen-Oslo</city>
        <zip>N-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Lilleby, M.D ass prof</last_name>
    </contact>
    <investigator>
      <last_name>Wolfang Lilleby, M.D ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Stranne, ass prof</last_name>
    </contact>
    <investigator>
      <last_name>Johan Stranne, M.D ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>SE 901 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camilla Thellenberg, M.D PhD</last_name>
    </contact>
    <investigator>
      <last_name>Camilla Thellenberg-Karlsson, M.D PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala Akademiska Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE 751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Johanssson, M.D</last_name>
      <email>eva.m.johansson@akademiska.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2014</study_first_submitted>
  <study_first_submitted_qc>March 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Olof Akre</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Prostatic neoplasms</keyword>
  <keyword>Locally advanced</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Surgery</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

